Biocon, Lupin, Prism Cement & KPR Mills reports: Indianivesh

Please Share::

�� India Equity Research Reports, IPO and Stock News Visit http://indiaer.blogspot.com/ for complete details ��

��

-->
 News Updates
Biocon: The Merck-Cubist Pharma deal could delay higher off-take of API for Fidaxomycin |
Maintain HOLD with PT of Rs479 | At CMP of Rs462, the stock is trading at 19.8x FY15E
EPS of Rs23 and 17.2x FY16E EPS of Rs26.9. We continue to value the stock at 18x
FY16E EPS of Rs26.9 to arrive at price target of Rs479 and maintain HOLD rating on
the stock.

 Research Update included
NiveshMonthly (Lupin & Prism Cement) | December 2014

Initiating Coverage | KPR Mills Ltd. | Taking advantage of complete integration.... | CMP:
Rs.370 | Rating: BUY | Target: Rs.570 (Refer to our detailed report released on 5th December
2014)

LINK
http://www.indianivesh.in/Admin/Upload/635537978280000000_NiveshDaily%20-%208%20December%202014.pdf